Vera Therapeutics, Inc., a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, announced an underwritten public offering of 7,058,824 shares of its Class A common stock at a price to the public of US$42.50 per share, which includes the exercise in full by the underwriters of their option to purchase up to 920,716 additional shares of its Class A common stock. The gross proceeds to Vera Therapeutics from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are approximately US$300 million. The offering closed on December 11, 2025.
Latham & Watkins LLP represented Vera Therapeutics in the offering with a Capital Markets team led by partners Keith Halverstam and Elisabeth Martin, with associates Amanda Farrish and Jessica Kerr, and assistance from Chanie Saltzman. Advice was also provided on FDA matters by partner Elizabeth Richards and counsel Chad Jennings, with associate Evan Miller; on healthcare matters by partner Betty Pang; on tax matters by partner Katharine Moir, with associate Dennis Poehland; and on public company representation matters by counsel Emily Corbi.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
